Drug Profile
GSK 4069327A
Alternative Names: Flexyn2a; GSK-4069327A; GVXN-SD133; Shigella 4V; Shigella dysenteriae bioconjugate vaccine - GlycoVaxyn; Shigella flexneri 2a vaccine - GlycoVaxyn; Shigella vaccine - LimmaTech BiologicsLatest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator GlycoVaxyn
- Developer GlycoVaxyn; Johns Hopkins Bloomberg School of Public Health; LimmaTech Biologics
- Class Bacterial vaccines; Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Shigella infections
Most Recent Events
- 01 Mar 2024 LimmaTech Biologics withdraws a phase-ISIS4V trial in Shigella infections (Prevention, In adults) in England (IM, Injection), due to lack of staff, facilities and resources (EudraCT2023-000129-10) (ISRCTN31763161)
- 26 Feb 2024 Interim adverse events and immunogenicity data from a phase I/II trial in Shigella infections released by LimmaTech Biologics
- 20 Jul 2023 GlaxoSmithKline Biologicals enters into licensing agreement with LimmaTech Biologics for GSK 4069327A